|
CFCF is pleased to announce that this E-Update is supported by Novartis Pharmaceuticals Corporation |
 Follow us on Twitter!
 Join us on Facebook!
Visit us on Navigating Cancer! |
Submitted 11/2010
CFCF is honored to present Survivor Stories. They reflect remarkable courage and determination. Thank you to our Survivors for sharing their courage and words of hope with other patients. Read our newest survivor stories:
|
|
Join Us for a Cure
Make a difference and get involved with CFCF! Unite, meet fellow members of the carcinoid community, and spread awareness at upcoming CFCF events! |
Give hope and a future to neuroendocrine tumor patients: donate to CFCF where 100% of all individual donations go to carcinoid and related neuroendocrine tumor research. CFCF is a 501(c)(3) organization-all contributions are tax-deductible. We want our donors to know that we are allocating their donations responsibly and wisely to achieve a carcinoid cure as quickly as possible.
To learn more, view CFCF's:
Audited Financial Statements
IRS From 990
|
CFCF meets all 20 Wise Giving Alliance standards for charity accountability established by the Better Business Bureau. Click here to check out the CFCF Wise Giving Report. |
|
|
|
|
|
|
CFCF-Funded Researchers Illuminate Genetic Code for Pancreatic Neuroendocrine Tumors
 With great excitement, we announce publication of significant and highly promising research results in Science, one of the world's most prestigious scientific journals. An abstract of the study entitled "DAXX/ATRX, MEN1 and mTOR Pathway Genes are Frequently Altered in Pancreatic Neuroendocrine Tumors" was published online in Science Express on January 20, 2011.
The study, led by Nickolas Papadopoulos, Ph.D. at Johns Hopkins University, uncovered the most commonly mutated genes in patients with non-functional pancreatic neuroendocrine tumors. Papadopoulos stated, "One of the most significant things we have learned is that each patient with this form of pancreatic cancer has a unique genetic code that predicts how aggressive the disease is and how sensitive it is to specific treatments."
Results suggest new approaches for treating patients with pancreatic neuroendocrine tumors. With few treatment options currently available for pancreatic neuroendocrine tumor patients, these findings represent important advances toward improving treatment options for these patients.
Click here to read the article abstract from Science Express.
Click here to read the press release issued by CFCF. |
|
CFCF Directors Discuss the Exciting Pancreatic Neuroendocrine Tumor Genome Project Results
In their latest blog entries, CFCF's Founder, Nancy Lindholm, and Executive Director, Lauren Erb discuss the promising results of Dr. Papadopoulos' study at Johns Hopkins and the implications for neuroendocrine tumor patients.
|
|
CFCF Clinical Trials Neuroendocrine Tumor Patient Education Conference in Los Angeles
 We are pleased to announce that CFCF will return to Los Angeles for a Neuroendocrine Tumor Patient Education Conference on March 19, 2011. The half-day conference will focus on clinical trials and feature expert speakers from Cedars-Sinai and UCLA. Click here to view the agenda featuring Dr. Wolin from Cedars-Sinai, Dr. Hecht from UCLA, and Lauren Erb from CFCF. The conference is part of CFCF's third annual Patient Education Weekend. The weekend will include the Los Angeles 5K Run/Walk (March 19), a Friends of CFCF Luncheon (March 19), and the Los Angeles Marathon (March 20). To learn more about the conference and for details on how to register, please visit our website or call 617.848.3977. |
|
|
|
|
